论文部分内容阅读
目的评估在实际生活条件影响下轻度持续性支气管哮喘(哮喘)患儿单独使用孟鲁司特进行控制治疗的效果。方法选取2～14岁在社区进行治疗的轻度持续哮喘患儿,进行前瞻性、单组、非盲观察性研究。孟鲁司特每天1次,2～5岁年龄组每次4 mg,6～14岁年龄组每次5 mg,持续12周,患儿通过监护人员给药,采取门诊复诊、随访的方式进行治疗及评估。分别在研究的0、4、8、12周,对过去7 d的日间症状、夜间症状进行严重程度评分,对峰值流速(PEF)、短效β2受体激动剂使用量进行检测和记录。采用SPSS 16.0统计软件进行统计分析。结果 2个年龄组日间症状、夜间症状严重程度评分在各随访时间点的评分逐步降低,各相邻时间点均数差异有统计学意义(P<0.05);短期使用短效β2受体激动剂的量明显下降,从第0周到第4周观察到显著的减少量(P<0.05);PEF不断改善,终点观察值(第12周)与起始值(第0周)比较差异有统计学意义(P<0.05)。结论对轻度持续哮喘患儿在社区实际生活条件影响下单用孟鲁司特仍可以有效控制哮喘症状的发作。
Objectives To assess the efficacy of montelukast in the treatment of patients with mild persistent bronchial asthma (asthma) under the influence of actual living conditions. Methods A prospective, single-group, non-blind observational study was conducted in children with mild persistent asthma who were treated in the community from 2 to 14 years of age. Montelukast once a day, 2 to 5 age group 4 mg each time, 6 to 14 age group of 5 mg each for 12 weeks, the children were administered by guardians, take outpatient referral, follow-up manner Treatment and assessment. At day 0, 4, 8 and 12 of the study, the severity of daytime symptoms and nocturnal scores of the past 7 days were scored and the peak flow rate (PEF) and the amount of short-acting β 2 receptor agonist were detected and recorded. Using SPSS 16.0 statistical software for statistical analysis. Results The scores of daytime symptom and nocturnal severity of symptom decreased gradually at each time point of the follow-up, and there were significant differences between the two adjacent time points (P <0.05). Short-term use of short-acting β2 receptor agonist (P <0.05). PEF improved continuously. There was statistical difference between the end point observation value (12th week) and the initial value (0th week) Significance (P <0.05). Conclusion Montelukast can still effectively control the onset of asthma symptoms in children with mild persistent asthma under the influence of the actual living conditions in the community.